|
14 Dec 2018 |
Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
|
|
14 Dec 2018 |
Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018
|
|
14 Dec 2018 |
Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints
|
|
14 Dec 2018 |
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
|
|
13 Dec 2018 |
Novartis receives European Commission approval for self-administration of Xolair® across all indications
|
|
13 Dec 2018 |
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
|
|
11 Dec 2018 |
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
|
|
11 Dec 2018 |
Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015
|
|
11 Dec 2018 |
Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead
|
|
09 Dec 2018 |
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-enhanced CD20 monoclonal antibody
|
|
09 Dec 2018 |
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium
|
|
09 Dec 2018 |
MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
|
|
07 Dec 2018 |
Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer
|
|
07 Dec 2018 |
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
|
|
06 Dec 2018 |
Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
|
|
06 Dec 2018 |
Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
|
|
06 Dec 2018 |
GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
|
|
06 Dec 2018 |
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
|
|
06 Dec 2018 |
Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted
|
|
06 Dec 2018 |
Eisai and UCL Commence Preparations for Phase I Clinical Studies in Alzheimer's Disease for Novel Anti-Tau Antibody E2814 Discovered Through Joint Research
|
|
05 Dec 2018 |
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
05 Dec 2018 |
Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
|
|
05 Dec 2018 |
Celltrion Healthcare presents positive results for CT-P10, biosimilar rituximab, in advanced follicular lymphoma at the American Society of Hematology Meeting 2018
|
|
05 Dec 2018 |
Generon Presented Pre-Clinical Immunotherapy Results With CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format
|
|
05 Dec 2018 |
Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101
|
